Skip to content

Reduction of hypertrophic scars and keloid by use of corticosteroid cream after removal of a tunneled central venous catheter in childhood cancer survivors

Reduction of hypertrophic scars and keloid by use of corticosteroid cream after removal of a tunneled central venous catheter in childhood cancer survivors

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-015163-14-DK
Enrollment
60
Registered
2009-11-30
Start date
2010-01-08
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Development of hypertrophic and keloid scars after removal of tunneled central venous catheters in childhood cancer survivors MedDRA version: 12.0 Level: LLT Classification code 10020879 Term: Hypertrophic scar MedDRA version: 12.0 Level: LLT Classification code 10023330 Term: Keloid scar

Interventions

Trade Name: Fucicort Pharmaceutical Form: Cream INN or Proposed INN: betamethasone CAS Number: 2152-44-5 Other descriptive name: BETAMETHASONE VALERATE Concentration unit: mg/g milligram(s)/gram Pharm

Sponsors

Department of Pediatrics Aarhus University Hospital Skejby
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Children aged 0-17 years treated for cancer at the Department of Pediatrics at Aarhus University Hospital Skejby, who have had a tunneled central venous catheter and who have the catheter removed due to end of treatment in the study period. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: known allergy towards fusidic acid or plaster

Design outcomes

Primary

MeasureTime frame
Main Objective: To examine whether treament with corticosteroid cream after removal of tunneled central venous catheter can reduce the development of hypertrophic and keloid scars in childhood cancer survivors;Secondary Objective: ;Primary end point(s): Scar measurement by Vancouver Scar Scale 12 month after removal of the catheter

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026